Now showing items 1-6 of 6
New insights into molecular mechanisms of sunitinib-associated side effects
(American Association for Cancer Research, 2011-12)
[Abstract] The introduction of targeted therapy represents a major advance in the treatment of tumor progression. Targeted agents are a novel therapeutic approach developed to disrupt different cellular signaling pathways. ...
Fructose transporter Glut5 expression in clear renal cell carcinoma
[Abstract] Renal cell carcinomas (RCC) can be subclassified for general purposes into clear cell, papillary cell, chromophobe cell carcinomas and oncocytomas. Other tumours such as collecting duct, medullary, mucinous ...
Multiple biomarker tissue arrays: a computational approach to identifying protein-protein interactions in the EGFR/ERK signalling pathway
(BioMed Central, 2012-09-01)
[Abstract] Background. Many studies have demonstrated genetic and environmental factors that lead to renal cell carcinoma (RCC) and that occur during a protracted period of tumourigenesis. It appears suitable to identify ...
Sunitinib-induced asthenia: from molecular basis to clinical relief
(Taylor & Francis, 2011-11-01)
[Abstract] Asthenia-fatigue syndrome (AFS) is defined as a persistent, subjective sense of tiredness related to cancer or its treatment and greatly impacts quality of life among cancer patients. All tyrosine kinase inhibitors, ...
A novel procedure for protein extraction from formalin-fixed paraffin-embedded tissues
[Abstract] Most of the archived pathological specimens in hospitals are kept as formalin-fixed paraffin-embedded tissues (FFPE) for long-term preservation. Up to now, these samples are only used for immunohistochemistry ...
Crossing paths in Human Renal Cell Carcinoma (hRCC)
[Abstract] Historically, cell-signaling pathways have been studied as the compilation of isolated elements into a unique cascade that transmits extracellular stimuli to the tumor cell nucleus. Today, growing evidence ...